Copyright 2014 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
To the Editor In an article in JAMA Psychiatry, Sigmon and colleagues1 concluded that their findings “suggest that a meaningful subset of [prescription opioid]–dependent outpatients may respond positively to a 4-week taper plus naltrexone maintenance intervention.” It would seem this is an overly positive assessment.
First, the number of participants was very small; the best outcomes were achieved with just 22 individuals assigned to the 4-week taper group. Furthermore, the best was not particularly good since half of these individuals had relapsed to nonprescribed opioid use 4 weeks after detoxification was completed and before naltrexone maintenance could be initiated. Because opioid dependence is recognized as a chronic condition, the outcome beyond the 8 weeks of this trial would presumably be very substantially worse.
Newman RG. Prescription Opioid DependenceThe Clinical Challenge. JAMA Psychiatry. 2014;71(3):338. doi:10.1001/jamapsychiatry.2013.4530